Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Licensing and Other Arrangements - Novartis - NIS793 (Details)

v3.24.3
Acquisitions, Licensing and Other Arrangements - Novartis - NIS793 (Details)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2015
USD ($)
item
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2023
USD ($)
Licensing and other arrangements                
Revenue from contracts with customers   $ 25 $ 225 $ 6,050 $ 1,350      
Novartis International | License Agreement                
Licensing and other arrangements                
Agreement termination prior written notice period 180 days              
Number of performance obligations | item 1              
Cash payment received             $ 37,000  
Revenue from contracts with customers   0 $ 0 0 $ 0 $ 10,000 $ 37,000  
Maximum milestone payments entitled to receive $ 480,000              
Minimum period eligible to receive royalties 10 years              
Contract assets   0   0       $ 0
Contract liabilities   0   0       0
Capitalized contract costs   $ 0   $ 0       $ 0